* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download A Placebo-Controlled Trial on the Efficacy of Mentat in Managing
Survey
Document related concepts
Major depressive disorder wikipedia , lookup
History of psychosurgery in the United Kingdom wikipedia , lookup
Rumination syndrome wikipedia , lookup
History of psychiatry wikipedia , lookup
Dissociative identity disorder wikipedia , lookup
Conversion disorder wikipedia , lookup
Emergency psychiatry wikipedia , lookup
Moral treatment wikipedia , lookup
Controversy surrounding psychiatry wikipedia , lookup
Biology of depression wikipedia , lookup
Bipolar II disorder wikipedia , lookup
Transcript
(Probe (1993): (XXXIII), 1, 26-31) A Placebo-Controlled Trial on the Efficacy of Mentat in Managing Depressive Disorders K.P. Sharma, M.D., Scholar, Dept. of Shalya Tantra, H.K. Kushwaha, Asst. Professor, Dept. of Shalya Tantra and S.S. Sharma Associate Professor and Head of Shalya Dept., National Institute of Ayurveda (NIA), Jaipur, India. ABSTRACT Mentat was used in 20 patients with mild to moderate symptoms of depressive disorders in this placebo-controlled trial. They were divided into two groups for comparison. The trial lasted 8 weeks. Mentat exerted a positively effective antidepressant activity and did not produce any side effects. It is noteworthy that Mentat enabled the patients to regain self-confidence and look at things more objectively than before treatment. A soothing effect on the mind was observed. It is suggested that with the advent and use of Mentat no case of depression need be looked upon as hopeless. INTRODUCTION The most characteristic symptom of a depressive disorder in a patient is his over-pessimistic view of life. His mood is morose, swinging from sorrow to sadness and he has a completely dejected countenance. Clinicians use different psychiatric terms to describe the variations in moods of patients. Besides psychotherapy and electroconvulsive therapy (ECT), a number of chemotherapeutic agents have been tried to alleviate the symptoms of depressive disorders or to obtain a complete cure. Monoamine oxidase (MAO) inhibitors and a number of antidepressants are frequently used to treat depressive symptoms. But none of these can be said to have brought about satisfactory response in the patients for various reasons. Monoamine oxidase inhibitors may give rise to tremors, dizziness and oedema of the ankle. This drug is contraindicated in patients having liver diseases. Psychotherapy in the form of psychoanalysis and counselling often fails in the absence of innate cooperation by the patient with the therapist. Electroconvulsive therapy has sometimes been accused of causing memory impairment. The patient with respiratory infection cannot go in for ECT. Antidepressants like imipramine and amitriptyline have unwanted effects upon the respiratory, cardiovascular and central nervous systems, and may cause complications in pre-existing constipation, retention of urine, muscular twitching or mild cholestatic jaundice. Having experienced so many side-effects and toxic symptoms produced by MAO inhibitors and antidepressant compounds, it was thought appropriate to give a clinical trial to Mentat (The Himalaya Drug Co., Bangalore) for evaluating its clinical efficacy in treating the various symptoms of depressive disorders. Mentat is a herbal compound that contains a number of ingredients which have since long been known to possess the property of soothing the nerves and having a desired effect on the brain. One of its ingredients, Evolvulus alsinoides, has been used as a brain tonic. MATERIAL AND METHODS In this clinical study, 20 patients (15 males and 5 females), all brought by community social workers to our OPD, were included. It was initially the insistence of social workers that prompted the hospital staff to enter these patients for the present clinical study, though the gloom writ large on their faces showed that they had psychic problems of one type or another. Each patient was, therefore, individually interviewed to confirm or rule out the social worker’s version about the patient’s ailments. To maintain a good rapport, all the patients were encouraged to talk freely. The complaints volunteered by the patients and those revealed by questioning were noted separately. First of all, the patients’ present problems were noted down. Their family history, social position and atmosphere at home were elicited. The factors and periods that made them worse or better were also noted down in detail. Enquiries were made about their sleep and diurnal pattern, their appetite and bowel movements. Their particular aversions and desires and their past and present ideas concerning their future were also elicited. The married patients were asked to how they were getting along with their spouses, as also about their attitude to sex. It was also ascertained whether or not they had been under any treatment for their ailments before coming to us at the NIA. If yes, the drug and duration of treatment along with improvement, if any, under previous treatment were noted. Their blood pressure, weight and pulse rates were also recorded. DIAGNOSTIC CRITERIA The criteria for including the patients in this clinical study were the presence of most of the clinical features of the depressive syndrome — a pessimistic view of life, poor appetite, loss of weight and a sleep pattern characterised by early morning waking and a changed diurnal pattern that usually follows the depressive disorder. One of the patients had earlier been taking a hypotensive drug that was the cause of his lethargy and low mood. He was asked to contact his previous physician for further consultation and was, therefore, excluded from the study. The 20 patients, diagnosed as having mild to moderate symptoms of depressive disorders, were divided into two equal groups. The allocation of patients to different groups was done at random. Eventually, the first group consisted of 7 male and 3 female patients, while the second group had 8 male and 2 female patients (Table I). Table I : Showing random distribution of patients in the two groups Males Females Group I (Mentat) 7 3 Group II (Placebo) 8 2 The patients of the first group (Mentat group) were given Mentat, 2 tablets b.i.d., while those of the second group (placebo group) were put on placebo. The blood pressure, weight and pulse rates along with any changes in their moods and facial expression were recorded regularly on a day-to-day basis for one week and thereafter at an interval of one week for 8 weeks. Patients’ self-rating of depression along with manifest changes in their facial expressions from gloom to that of cheerfulness and an increase in self-confidence to cope with their problems themselves and restoration of normalcy in sleep pattern were taken as parameters for measuring improvement in patients’ depressive symptoms. The antidepressant activity of this clinical trial was considered positive only if there was more than 80% reduction in severity of total symptoms score in an individual patient. A reduction of 50% to 75% in symptoms was rated as moderate to marked and 81% to 100% as good as excellent. Patients scoring less than 50% improvement were regarded as unchanged. The findings observed in this study were properly analysed and compared between the two groups. OBSERVATION, ANALYSIS AND DISCUSSION In the present clinical study, it was found that males are more prone to develop depressive disorders than females and the child is less prone to develop depressive symptoms and still less th female child although such a one was absent in this study (Table II). Table II : Showing age and sex incidence of patients Age in years Males Females 10 to 20 1 — 21 to 40 10 3 41 to 60 4 2 15 5 Married persons seemed more sensitive to develop symptoms of depressive disorders than unmarried ones (Table III). Male Female Table III : Showing marital status of patients Unmarried Married Divorced 5 10 — 4 1 — 9 11 — This may be due to the presence of undesired interaction between couples. As depicted in Table IV, a pessimistic view of life, troubled sleep, constipation, loss of appetite and weight and changed diurnal pattern were prevalent symptoms that were exhibited by the patients in the study. Agitation was found only in four male patients. Menstrual disturbance appeared a common symptom in 3 out of 5 female patients. Table IV : Showing prevalence of symptoms of depressive orders Symptoms Males Females 1. Pessimistic view of life 12 4 2. Poor appetite 10 4 3. Constipation 13 4 4. Troubled sleep 15 5 5. Loss of weight 10 4 6. Delusions — — 7. Hallucinations — — 8. Changed diurnal pattern 11 3 9. Agitation 4 — 10. Menstrual disturbance — 3 After 8 weeks of trial with both regimens it was found that moderate to marked reduction in symptoms was manifest in 2 patients in Group I (Mentat). Two patients in this group were able to score good to excellent results. It was also observed that a maximum of six patients in the Mentat group were able to achieve positive improvement. In contrast to this, neither good to excellent nor positive results were obtained by any of the patients taking the placebo. However, 4 patients of the placebo group could achieve a moderate to marked score, while depressive symptoms of six patients in the same group remained unchanged. No toxic symptoms of any nature seemed to have developed in patients taking Mentat. It was observed that Mentat helped patients revive their faith in life and gain confidence to solve their problems themselves. After treatment with Mentat, the patients were able to look at things more objectively than before, whereas no such pleasant psychological change was found in patients who were on placebo. It appears that some of the ingredients of Mentat have a soothing effect on the mind. RESULTS The clinical efficacy of Mentat, an indigenous compound, was assessed and evaluated in 10 patients of depressive disorders against an equal number of such patients who were on placebo. It was observed that Mentat possesses a positively effective antidepressant activity and does not produce any toxic symptoms. Mentat is useful in managing depressive disorders, and some of their pathetic symptoms can be successfully controlled within a short duration by the use of Mentat (Table V). Table V : Showing improvement in score in the two groups of patients after 8 weeks of trial Improvement rating Group Unchanged Moderate to Marked Positive Good to Excellent Group I — 2 6 2 (Mentat) Group II 6 4 — — (Placebo) SUMMARY Life is full of joys and sorrows. Sorrows or problems are a natural part of life and have to be faced, dealt with and solved. When one finds oneself unable to solve one’s problems, he or she becomes confused, unhappy, bewildered, unsure and ultimately succumbs to a depressive disorder. Despite intensive research, the treatment of depressive disorders was until recently limited primarily to a few time-tested drugs which relieved the symptoms temporarily, while simultaneously producing various side-effects. This sorry picture changed during the present clinical study, wherein a placebocontrolled trial was conducted to evaluate the efficacy of Mentat in the management of depressive disorders. A few of the findings of the present study substantiate the earlier observations made by Sharma, A.K. and others who have tried Mentat in cases of depression. Obviously, while there is no `magic bullet’ for treating depressive disorders, yet with the advent and use of Mentat no case of depression seems completely hopeless. Even if the depressive disorder gallops out of control, most of its pathetic symptoms can be minimised by the use of Mentat. Mentat is a “mood maker” and changes the mood from morose to mellow, from sullen to sweet. ACKNOWLEDGEMENTS Our grateful thanks are due to the Head of the NIA Hospital, Jaipur for according permission to publish this report. We (KPS & HKK) are thankful also to the Head of Department (Shalya), Dr. S.S. Sharma for his kind co-operation and supervision to conduct the study, as well as the doctors, nursing staff at NIA and concerned social workers for their co-operation in handling the patients. Thanks also to The Himalaya Drug Co., Bombay for a liberal supply of Mentat to conduct the study.